Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CSPC PHARMACEUTICAL GROUP LIMITED
石藥集團有限公司
(Incorporated in Hong Kong with limited liability)
(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

PHASE II CLINICAL TRIAL OF SYH9061 FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS OFFICIALLY INITIATED AT THE FIRST CENTRE IN CHINA

The Board of Directors (the "**Board**") of CSPC Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that the Phase II clinical trial of SYH9061 (the "**Product**") developed by the Group for the treatment of idiopathic pulmonary fibrosis ("**IPF**") has been officially initiated at the first centre in China.

The Product is a nintedanib powder for inhalation and is classified as a Class 2.2 chemical drug. Nintedanib is a tyrosine kinase inhibitor which, by competitively binding to the adenosine triphosphate (ATP) binding site in the intracellular receptor kinase domains, inhibits vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR), thereby blocking intracellular signal transduction and inhibiting the proliferation, migration and transformation of fibroblasts. Nintedanib possesses anti-fibrotic and anti-inflammatory activities, and can slow the progression of pulmonary fibrosis and delay the disease progression of IPF. Formulated as a powder for inhalation, the Product delivers nintedanib directly to the target organ, increasing pulmonary drug exposure while reducing systemic plasma concentrations, thereby decreasing gastrointestinal adverse reactions.

Previously, the Group received the Notice of Approval for Clinical Trial of Drug for the Product issued by the National Medical Products Administration of the People's Republic of China in December 2025 and, following the approval, the Group promptly initiated a single-centre, randomised, double-blind, placebo- and active-controlled, single and multiple ascending dose Phase I clinical trial to evaluate the safety, tolerability and pharmacokinetic profile of the Product in healthy male participants in China. Data from this Phase I clinical trial have preliminarily verified the pharmacokinetic profile of the Product in humans and shown favourable results.

The clinical trial initiated this time is a multi-centre, randomised, blinded, placebo- and active-controlled Phase II clinical trial, aiming to evaluate the efficacy and safety of the Product in adult participants with IPF in China. Currently, the recruitment and screening of participants for this clinical trial are actively underway.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 6 November 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.